A single study in the literature explored IL-6 as a predictor in HCC patients receiving sorafenib (55 and 73 patients in exploration and validation cohorts) showed a cut-off value of 4.28 pg/mL could predict survival (HR, 2.5 [1.3–5.0], p = 0.005) in an Asian cohort (Shao et al. 2017). Here, IL6 is linked to hepatocellular carcinoma.